Cancer Research UK

cancerresearchuk.org

Total trials

84

Active

14

Phase 3

15

Total enrollment

47,993

Read this sponsor's pipeline like an analyst.

Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.

~15-30 sec · cached for 24h

Pipeline matrix

Showing 21 of 21 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Alectinib2
Atezolizumab2
Entrectinib2
Capmatinib2
Vemurafenib1
Cobimetinib1
Trastuzumab1
Pertuzumab1
Trastuzumab in combination with pertuzumab1
Vemurafenib in combination with cobimetinib1
Dabrafenib1
Trametinib1
TT-7021
Darolutamide1
ALETA-0011
HTL00397321
HTL0039732 Capsules and atezolizumab1
UCB45941
HMBD-0011
HMBD-001 and enzalutamide1
LY3143921 hydrate1

Next readouts

  • 2025-11
  • 2027-02-28
  • 2027-06
  • 2027-06
  • 2028-02
  • 2029-10
  • 2029-10
  • 2029-10
  • 2029-10
  • 2029-10

Top conditions

  • Lymphoma12
  • Haematological Malignancy7
  • Colorectal Neoplasms7
  • Solid Tumour7
  • Breast Cancer7
  • Cancer7
  • Ovarian Cancer6
  • Unspecified Adult Solid Tumor, Protocol Specific6

Frequently asked questions about Cancer Research UK

How many clinical trials does Cancer Research UK have on ClinicalTrials.gov?
Cancer Research UK is listed as the lead sponsor on 84 clinical trials in ClinicalTrials.gov, 14 of which are currently active (recruiting, enrolling, or ongoing).
How many of Cancer Research UK's trials are in Phase 3?
15 of Cancer Research UK's trials are in Phase 3, spread across 21 active drug programs.
What therapeutic areas does Cancer Research UK focus on?
Cancer Research UK's most-studied conditions on ClinicalTrials.gov are Lymphoma, Haematological Malignancy, Colorectal Neoplasms, Solid Tumour, Breast Cancer.
When are Cancer Research UK's next clinical trial readouts?
Cancer Research UK has 10 upcoming primary-completion readouts tracked here; the soonest is “A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours”, expected around 2025-11.